Medifast CEO Buys $178K in Company Stock

Daniel Chard acquires nearly 18,000 shares amid stock price decline

Mar. 29, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Medifast Inc. (NYSE:MED) CEO Daniel Chard purchased 17,678 shares of the company's stock on March 20th at an average price of $10.11 per share, totaling a $178,724 investment. The transaction represents a significant increase in Chard's direct ownership of Medifast stock, which has seen its price drop from a 52-week high of $15.46.

Why it matters

Insider buying can be a positive signal to investors, indicating that company leadership believes the stock is undervalued and has confidence in the business's future prospects. Medifast has faced challenges recently, with its stock price declining amid broader market volatility, so Chard's substantial purchase could be seen as a vote of confidence in the company's long-term outlook.

The details

Chard's purchase of 17,678 Medifast shares was disclosed in a filing with the Securities and Exchange Commission. The transaction was executed on March 20th at an average price of $10.11 per share, totaling an investment of $178,724.58. Following the purchase, Chard now directly owns 17,678 shares in the company, which has a current market capitalization of around $106 million.

  • Chard purchased the 17,678 Medifast shares on March 20, 2026.
  • Medifast's stock price has ranged from a 52-week low of $9.22 to a 52-week high of $15.46 over the past year.

The players

Daniel Chard

CEO of Medifast Inc., a health and wellness company specializing in weight-loss and nutrition products.

Medifast Inc.

A publicly traded company (NYSE:MED) that provides clinically supported weight-loss, weight-management, and healthy living products and services.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching to see if Chard's insider purchase signals a potential turnaround for Medifast's stock price, which has declined in recent months. The company's next earnings report, scheduled for early May, will provide further insight into its financial performance and outlook.

The takeaway

Chard's substantial investment in Medifast stock during a period of market volatility and a declining share price suggests he believes the company is undervalued and has confidence in its long-term potential. Insider buying can be a positive signal, but investors should also closely monitor Medifast's upcoming financial results and strategic initiatives.